两名携带FLT3-ITD突变的急性髓系白血病（AML）患者对索拉非尼产生继发性耐药。 - Suppr

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.

作者信息

Scholl Sebastian, Spies-Weisshart Baerbel, Klink Anne, Muegge Lars-Olof, Fricke Hans-Joerg, Hochhaus Andreas

出版信息

Ann Hematol. 2011 Apr;90(4):473-5. doi: 10.1007/s00277-010-1027-9. Epub 2010 Jul 21.

DOI:10.1007/s00277-010-1027-9

PMID:20652568

Abstract

摘要

相似文献

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.

Ann Hematol. 2011 Apr;90(4):473-5. doi: 10.1007/s00277-010-1027-9. Epub 2010 Jul 21.

Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.

Am J Hematol. 2009 Oct;84(10):701-2. doi: 10.1002/ajh.21511.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.

Acta Haematol. 2010;124(3):153-9. doi: 10.1159/000320173. Epub 2010 Oct 11.

Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.

Leuk Res. 2011 Mar;35(3):e21-2. doi: 10.1016/j.leukres.2010.10.028. Epub 2010 Dec 8.

A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.

Leuk Res. 2010 Oct;34(10):e268-9. doi: 10.1016/j.leukres.2010.03.046. Epub 2010 Apr 24.

Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.

Leuk Res. 2011 Mar;35(3):422-3. doi: 10.1016/j.leukres.2010.10.025. Epub 2010 Nov 18.

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

Leuk Res. 2009 Feb;33(2):348-50. doi: 10.1016/j.leukres.2008.04.017. Epub 2008 Jun 24.

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

Leukemia. 2012 Nov;26(11):2353-9. doi: 10.1038/leu.2012.105. Epub 2012 Apr 16.

Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.

Br J Haematol. 2012 Aug;158(4):555-8. doi: 10.1111/j.1365-2141.2012.09189.x. Epub 2012 Jun 12.

引用本文的文献

A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia.

Int J Mol Sci. 2023 Feb 14;24(4):3830. doi: 10.3390/ijms24043830.

Retracted Article: LncRNA ZEB2-AS1 regulates the drug resistance of acute myeloid leukemia the miR-142-3p/INPP4B axis.

RSC Adv. 2019 Dec 2;9(67):39495-39504. doi: 10.1039/c9ra07854a. eCollection 2019 Nov 27.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.

Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Am J Blood Res. 2013;3(1):29-51. Epub 2013 Jan 17.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献